Abiopharma

🔍 Redmile Group, LLC (Director)

Company: Shattuck Labs, Inc. (STTK)

Report Date: 2025-08-25

Detailed Transactions and Holdings:

• Acquired 4,097,730 shares of Pre-Funded Warrants to Purchase Common Stock at $0.0001 per share (Derivative)
  Date: 2025-08-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,198,553.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3
• Acquired 4,097,730 shares of Common Warrants to Purchase Common Stock at $1.0846 per share (Derivative)
  Date: 2025-08-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,097,730.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3

Footnotes:

• F1: On August 25, 2025 (the "Closing Date"), pursuant to the terms of that certain securities purchase agreement, dated as of August 4, 2025 (the "Purchase Agreement") and following the satisfaction of certain material conditions set forth therein, the Issuer issued and sold to certain institutional investors in a private placement, including certain private investment vehicles managed by Redmile Group, LLC (the "Redmile Clients"), pre-funded warrants (the "Pre-Funded Warrants") to purchase shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), accompanied by warrants (the "Common Warrants") to purchase an equal number of shares of Common Stock (or, in lieu thereof, Pre-Funded Warrants to purchase up to the same number of shares), at a combined purchase price for both securities of $0.8676.
• F2: The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial.
• F3: The reported securities are directly owned by the Redmile Clients, and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as the investment manager of the Redmile Clients.
• F4: The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• REMARKS: Mr. Michael Lee, a managing director of Redmile, resigned as a member of the board of directors of the Issuer effective as of the Closing Date.